Comparative Pharmacology
Head-to-head clinical analysis: EXCEDRIN MIGRAINE RELIEF versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXCEDRIN MIGRAINE RELIEF versus PARAFON FORTE DSC.
EXCEDRIN (MIGRAINE RELIEF) vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: inhibits COX enzymes centrally, reducing prostaglandin synthesis; Aspirin: irreversibly acetylates COX-1 and COX-2, inhibiting prostaglandin synthesis and platelet aggregation; Caffeine: adenosine receptor antagonist, enhances analgesic effect by vasoconstriction and increased drug absorption.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine) orally every 6 hours as needed, not to exceed 6 tablets in 24 hours.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
Acetaminophen: 2-3 hours (terminal); aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours (low dose), 15-30 hours (high dose); caffeine: 3-7 hours (adults). Clinical context: Half-lives prolonged in hepatic impairment, overdose, or renal failure.
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Renal excretion: acetaminophen ~3% unchanged, metabolites (glucuronide, sulfate, cysteine, mercapturate) ~85%; aspirin as salicylic acid ~10% unchanged, metabolites (salicyluric acid, glucuronides) ~75% renal; caffeine ~1-5% unchanged, metabolites (paraxanthine, theobromine, theophylline) ~70% renal. Biliary/fecal <5%.
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Analgesic Combination
Muscle Relaxant/Analgesic Combination